Compare KIDZW & GRMLW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KIDZW | GRMLW |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | 5 |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | 2022 |
| Metric | KIDZW | GRMLW |
|---|---|---|
| Price | $0.02 | $0.24 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 53.5K | 9.2K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.01 | $0.10 |
| 52 Week High | $0.42 | $0.37 |
| Indicator | KIDZW | GRMLW |
|---|---|---|
| Relative Strength Index (RSI) | 52.03 | 71.81 |
| Support Level | $0.01 | $0.11 |
| Resistance Level | $0.02 | N/A |
| Average True Range (ATR) | 0.00 | 0.04 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 15.52 | 42.67 |
Classover Holdings Inc is an education technology company based in New York. It provides comprehensive online interactive live courses for K-12 students in the United States and around the globe. Its curriculum is designed to meet the needs of different age groups and learning levels, covering various subjects to enhance students' academic achievements and interest in exploration. The company offers both interest-oriented classes and test preparation courses for various exams and competitions. With its approach, Classover aims to transcend the boundaries of traditional education by offering students a comprehensive set of lifelong skills and capabilities, including creativity, critical thinking, and problem-solving, in an engaging and interactive environment.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.